Corporate

Insider Transactions

Showing insider trading activity for Accardi Mario Alberto.

Insider Trading Activity Chart

Visualizing insider transactions on stock price candles

Transaction Type
Insider Role
Min Transaction Value

No stock price data available.

Recent Filings
SymbolNameFiledTransactionTypeRoleShares
CNTAAccardi Mario Alberto18 May 20261 May 2026F-InKinddirector, officer: Chief Executive Officer604
CNTAAccardi Mario Alberto3 Feb 20261 Feb 2026F-InKinddirector, officer: Chief Executive Officer2,915
CNTAAccardi Mario Alberto3 Feb 20262 Feb 2026A-Awarddirector, officer: Chief Executive Officer68,000
CNTAAccardi Mario Alberto3 Feb 20262 Feb 2026A-Awarddirector, officer: Chief Executive Officer273,000
CNTAAccardi Mario Alberto9 Dec 20259 Dec 2025S-SalePresident, Orexin Program7,432
CNTAAccardi Mario Alberto9 Dec 20259 Dec 2025S-SalePresident, Orexin Program2,568
CNTAAccardi Mario Alberto8 Dec 20258 Dec 2025M-ExemptPresident, Orexin Program5,000
CNTAAccardi Mario Alberto8 Dec 20258 Dec 2025S-SalePresident, Orexin Program10,000
CNTAAccardi Mario Alberto8 Dec 20258 Dec 2025M-ExemptPresident, Orexin Program5,000
CNTAAccardi Mario Alberto3 Nov 20251 Nov 2025F-InKindPresident, Orexin Program593
CNTAAccardi Mario Alberto27 Oct 202527 Oct 2025M-ExemptPresident, Orexin Program5,000
CNTAAccardi Mario Alberto27 Oct 202527 Oct 2025S-SalePresident, Orexin Program8,000
CNTAAccardi Mario Alberto27 Oct 202527 Oct 2025M-ExemptPresident, Orexin Program5,000
CNTAAccardi Mario Alberto16 Sept 202516 Sept 2025S-SalePresident, Orexin Program7,430
CNTAAccardi Mario Alberto16 Sept 202516 Sept 2025S-SalePresident, Orexin Program742
CNTAAccardi Mario Alberto11 Sept 20259 Sept 2025M-ExemptPresident, Orexin Program5,000
CNTAAccardi Mario Alberto11 Sept 20259 Sept 2025S-SalePresident, Orexin Program7,000
CNTAAccardi Mario Alberto11 Sept 20259 Sept 2025M-ExemptPresident, Orexin Program5,000
CNTAAccardi Mario Alberto1 Aug 20251 Aug 2025F-InKindPresident, Orexin Program597
CNTAAccardi Mario Alberto30 Jul 202529 Jul 2025S-SalePresident, Orexin Program8,322